Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Oncolytics Biotech Inc.NASDAQ: ONCY

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of CA$6.57M rose 133.2% year over year, ahead of the +58.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 119.7% from the prior quarter. Over 3 fiscal years it compounded at +35.4% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of CA$0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +58.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$6.57M+119.7% QoQ
Last fiscal yearDec 2025
CA$21.15M+58.6% YoY
LTMMar 2026
CA$18.6M+58.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+133.2%-100.0%-233.2 pp
1 year+58.6%-100.0%-158.6 pp
3-year CAGR+35.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CAD · from the income statement

Latest · FY2025
21.15M CAD
Year-over-year change
+58.6%
4-year CAGR
+19.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +58.0% is the 2nd highest of 9, against a peer median of -31.0%.
  • Over three fiscal years its annual growth of +35.4% compares with a peer median of -10.5%.
ONCY Competitors
Selling, General & Admin for ONCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$6.7B USD+73001.9%+33.2%84342.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$34.97M USD-57.3%-11.6%—
TILInstil Bio, Inc.LTM Mar 2026$23.46M USD-41.6%-24.1%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$23.29M USD-40.2%-9.5%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$18.6M CAD+58.0%+35.4%—
SRZNSurrozen, Inc.LTM Mar 2026$18.36M USD+21.1%-6.5%244.9%
IMMXImmix Biopharma, Inc.LTM Mar 2026$15.81M USD+34.6%+50.4%—
CLNNClene Inc.LTM Mar 2026$7.9M USD-34.1%-17.0%5897.0%
Peer median (excluding ONCY) —-31.0%-10.5%3071.0%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue360.58K301.11K298.59K87K70K
Gross Profit(360.58K)(301.11K)(298.59K)(87K)(70K)
Gross Margin—————
Research & Development10.31M11.85M13.12M21.65M18.27M
Selling, General & Admin10.26M8.53M11.62M13.34M21.15M
Operating Expenses20.56M20.38M24.74M34.98M39.41M
Depreciation & Amortization360.58K301.11K298.59K102K96.05K
EBITDA(20.58M)(18.71M)(20.19M)(34.88M)(39.41M)
EBITDA Margin—————
Operating Income(20.93M)(20.68M)(25.04M)(34.98M)(39.41M)
Operating Margin—————
Interest Income99K528K1.33M1.2M529.64K
Interest Expense00000
Other Income / Expenses(15.88K)1.67M4.55M3.4M61.75K
Income Before Tax(20.94M)(19.01M)(20.49M)(31.58M)(39.35M)
Pre-Tax Margin—————
Income Tax Expense39.42K64.52K71.87K130K108.4K
Net Income(20.98M)(19.08M)(20.56M)(31.71M)(39.46M)
Net Margin—————
EPS (Basic)(0.49)(0.44)(0.41)(0.41)(0.41)
EPS (Diluted)(0.49)(0.44)(0.41)(0.41)(0.41)
Weighted Avg Shares53.51M58.03M67.62M76.48M95.86M
Weighted Avg Shares (Diluted)53.51M58.03M67.62M76.48M95.86M

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.